https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 3(3):42-45, 2024

©RIJBAS Publications

Online ISSN: 1115-6171

Print ISSN: 1597-2879

Personalized Medicine: Tailoring Treatments to Individual Genetic Profiles

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Personalised medicine tailors therapies to individuals' genetic profiles and predispositions, revolutionising healthcare. This strategy offers more precise and effective therapies, especially for complicated illnesses like cancer, than the one-size-fits-all concept. Advanced genetic profiling, next-generation sequencing, and bioinformatics techniques have permitted customised medicines, better results, and reduced side effects. However, personalised medicine raises ethical and legal issues including privacy, consent, and genetic prejudice. Personalised medicine's inclusion into mainstream healthcare might transform patient treatment, but it must be carefully considered in light of its social impacts.

Keywords: Personalized Medicine, Genetic Profiling, Pharmacogenomics, Next-Generation Sequencing (NGS), Precision Medicine.

INTRODUCTION

Personalized medicine involves tailoring healthcare to the unique genetic profiles and predispositions of individual patients. Traditionally, physicians have relied heavily on standardized treatments based on disease diagnoses. For example, the first line of treatment for high cholesterol or borderline high blood pressure is often a specific medication such as atorvastatin or hydrochlorothiazide, respectively. Further medications are then added or the doses adjusted according to each treatment's effect on the patient. This one-size-fits-all approach has worked well for many patients for common diseases such as diabetes or high blood pressure. However, for other conditions with more complex underlying biology, such as cancer, the variability in how patients respond to the same drug necessitates an alternative approach. The added challenge of designing treatments targeted to an individual's genetic makeup is offset by the possibility of more effective and precise medical interventions, sometimes with fewer side effects [1]. Personalized medicine is an evolving field with over 2,000 genetic tests available (many of which are related to cancer). The concept of targeting medical treatments based on an individual's unique characteristics is not new. One of the earliest breakthroughs in personalized medicine was the discovery in the 1950s that some patients with acute lymphoblastic leukemia responded well to aminopterin, a drug that blocked the action of the B vitamin, folic acid. It was observed that the drug was effective in patients whose cancer showed high levels of folic acid. This was the first time that a medical treatment was matched to the unique biological characteristics of a patient's cancer. Since then, variations in how patients respond to many other drugs based on their genetic makeup have been discovered [2, 3].

THE ROLE OF GENETICS IN PERSONALIZED MEDICINE

It has long been recognized that patient variations can influence the efficacy of medication. Personalized medicine's main point of view is to consider an individual's genetic factors that predispose to a particular therapy outcome and take them into account. A treatment strategy that integrates genetic, phenotypic, medical, environmental, and psychosocial information for the custom care of patients (including prevention, diagnosis, and therapy) is called personalized medicine. The genetic profiling or "targeted" medication methodology is another name for it. Many believe that it will revolutionize medicine in the next few years. Individual genetic variations may influence drug metabolism, disease development, infection susceptibility, and other cyclical factors. Because of these benefits, genetic testing in

personalized medicine is growing in popularity. Drug creators are increasingly developing diagnostic methods as companion marketing strategies [4]. Personalization refers to the process of creating an effective treatment that is customized to the individual. This custom therapy, however, is often divided by certain clinical or genetic identifiers. If the individual is genetically identified, their genetic code, also known as genotype, is used by the health team to direct the care. Though pharmacogenomic testing has had limited influence, improvements in technologies and research have helped to further expand the findings of genetic markers, or phenotypes, providing the benefits of rhythm. The use of genetic testing to recognize a particular condition represents the most readily adaptable approach in personalized medicine. Pharmacotherapy based on the patient's genetic profile has grown in popularity over the last few decades. Patients who have undergone genetic testing and are hence less sensitive to chemo drugs benefit significant improvements [5].

TECHNOLOGIES AND TOOLS FOR GENETIC PROFILING

Tremendous developments have been made during the last decade in technology to decipher the genetic information encoded in our DNA. The technologies include a wide array of highly parallel, high-throughput sequencing techniques (also called 'next-generation sequencing'), microarray technologies, and others. In addition to the hardware tools, vast numbers of software and bioinformatics tools are now available to assist in the interpretation of the data gathered. These include de novo assembly algorithms to assemble whole genomes, transcriptomes, and metagenomes, methods for comparing sequencing reads to reference sequences to find similarities that identify mutations, and other tasks, including a wide range of techniques designed to interpret the data gathered to develop predictive information of value for personalized medicine, including gene expression patterns, types and amounts of proteins being produced in the body, and the functions and properties of potential drug targets, among many other examples [6]. Central to the concept of personalized medicine is the ability to develop a genetic profile of a patient, allowing physicians to find out what makes a person unique. The process of developing a genetic profile is now known as 'genomic profiling'. This procedure requires determining the sequence of codes making up the genome of an individual. Going back as far as 2010, genomic tests were based on single targeted mutations or aimed to determine drug metabolism phenotypes using a small array of SNPs. Later, various types of genomic testing platforms emerged, allowing diverse levels of integration beginning from multi-gene panels, genome/exome sequencing (WES), and ending on whole genome and transcriptome/regulome sequencing (WTS). Data garnered from the DNA and RNA sequencing can be integrated and used to draw up experimental drugs in validated clinical trials or potential investigations to allow for better personalized treatment. Integrating next-generation sequencing (NGS) and advanced data analytics into a clinical setting for the purpose of delivering more personalized treatment through the use of precise genetic profiles of individuals and their conditions has consequently become quite an interesting topic and discipline [7].

ETHICAL AND LEGAL CONSIDERATIONS IN PERSONALIZED MEDICINE

The advent of personalized medicine has brought up profound ethical and legal questions. One fundamental concern in personalized medicine is the treatment of genetic information - such treatment has to respect the privacy of the individual as well as the right to autonomy. In addition, questions of consent for genetic testing and the individual's ability to interpret genetic information must be treated with particular care. Other issues of genetic discrimination and psychological impacts of genetic information have been heavily debated in the academic community. Several efforts to propose guidelines or legislation regulating the field have been started, but more regulation may be required in the era of personalized medicine [8]. Moreover, the implementation of personalized medicine at large scale might bring about not only scientific, but also social and economic inequalities. It is essential to adopt clear guidelines that will take into account the social and individual dimensions of personalized medicine to guarantee its responsible and accountable implementation. The European Union and the international community are currently discussing the roadmap and the perspectives of personalized medicine in the healthcare systems. Large-scale research and implementation of personalized medicine have already started, assessing the relationships of personalized medicine and privacy rights as crucial. Therefore, it has been advocated that more regulations and international guidelines should be put in place to guarantee the responsible implementation of personalized medicine [9, 10].

CASE STUDIES AND SUCCESS STORIES IN PERSONALIZED MEDICINE

Personalized medicine has had a marked impact in the past decade, revolutionizing patient care within oncology, hematology, and genetic disorders, among other areas. Certain disease states—such as cancer at stage 4—are generally associated with low survival rates. However, the discovery of specific genetic mutations and targets, as well as the development of drugs to address these targets, have shifted the paradigms of treatment [11]. For example, in chronic lymphocytic leukemia (CLL), the discovery of a B-

cell lymphoma 2 (BCL-2) mutation (20% of all CLL) fueled the development of venetaclax—a compound that leads to programmed cell death in these aggressive cancer cells. Prior to venetaclax, CLL had never seen a 5-year survival rate higher than 40%. Now, with the use of venetaclax in first-line and salvage settings, there is upwards of an 80% progression-free survival (PFS) at 5 years. In recent years, similar scenarios have been seen in thyroid carcinoma with progression on radioactive iodine uptake with the advent of Ret kinase inhibitors selpercatinib and lower catinib and pralsetinib demonstrating a median progression-free survival (mPFS) in all sarcoma subtypes with mTOR anomalies (3, 3, and 15.8 years, respectively) in round of phase 2 testing. Viddy Chaudhary, an oncologist specializing in personalized medicine, called the shift in treatment for these particular sarcoma, that previously only saw a PFS of about one year with first-line therapy, a "pretty huge jump." In addition to the RAVEEN trial, Chaudhary is also the principal investigator in camreports, an international, precision medicine pilot trial for more aggressive cancers. Overall, Chaudhary said that IRM trials and similar studies at the national level reflect a new way of thinking for precision medicine. "I truly believe that in less than 10 years [precision medicine] will be the standard of care," she said. "This has to become the way we treat people, because it's going to save so many lives" [12, 13].

CONCLUSION

Personalized medicine marks a significant advancement in the field of healthcare, offering a promising alternative to conventional treatment approaches by focusing on the genetic and molecular underpinnings of disease. By tailoring medical interventions to individual genetic profiles, personalized medicine has the potential to enhance treatment efficacy, minimize adverse effects, and improve patient outcomes. However, its widespread adoption requires addressing critical ethical, legal, and societal challenges, particularly concerning genetic privacy and equitable access to these advanced therapies. As the field progresses, the continued integration of personalized medicine into clinical practice will likely redefine the future of healthcare, making it more precise, effective, and patient-centered.

REFERENCES

1. YahyaAlmakrami I, Al Omorat T, GhannamShreaf MM, Al-Yami SA, Alyami KA. Tailoring Treatment to The Individual: A Critical Examination of Precision Medicine and Personalized Healthcare Through the Lens of Genetics, Lifestyle, And Environmental Factors. Chelonian Research Foundation. 2023 Jun 30;18(1):550-64. acgpublishing.com
2. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology. 2022. springer.com
3. Li Y, Tang P, Cai S, Peng J et al. Organoid based personalized medicine: from bench to bedside. Cell Regeneration. 2020. springer.com
4. Yoshida K, Müller DJ. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Molecular Neuropsychiatry. 2020. karger.com
5. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal-Cardiovascular Pharmacotherapy. 2022 Jan;8(1):85-99. sgul.ac.uk
6. Federici G, Soddu S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. Journal of Experimental & Clinical Cancer Research. 2020. springer.com
7. Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, Fernández-Brillet L, Fernández-Martínez JL, Kloczkowski A. Innovations in genomics and big data analytics for personalized medicine and health care: A review. International journal of molecular Sciences. 2022 Apr 22;23(9):4645. mdpi.com
8. Faulkner E, Holtorf AP, Liu CY, Lin H, Biltaj E, Brixner D, Barr C, Oberg J, Shandhu G, Siebert U, Snyder SR. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. Value in Health. 2020 May 1;23(5):529-39. sciencedirect.com
9. Venne J, Busshoff U, Poschadel S, Menschel R, Evangelatos N, Vysyaraju K, Brand A. International consortium for personalized medicine: an international survey about the future of personalized medicine. Personalized medicine. 2020 Mar;17(2):89-100. tandfonline.com
10. Ritzhaupt A, Hayes I, Ehmann F. Implementing the EU in vitro diagnostic regulation–a European regulatory perspective on companion diagnostics. Expert Review of Molecular Diagnostics. 2020 Jun 2;20(6):565-7. tandfonline.com

11. Hu HF, Ye Z, Qin Y, Xu XW, Yu XJ, Zhuo QF, Ji SR. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacologica Sinica. 2021 Nov;42(11):1725-41. nih.gov
12. Testa S, Bui NQ, Ganjoo KN. Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis. Cancer Research Communications. 2023. aacrjournals.org
13. Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Pellizzari G, Katrini J, Passaro A, de Marinis F. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs". Cancers. 2024 Aug 19;16(16):2877. mdpi.com

CITE AS: Nyiramana Mukamurera P. (2024). Personalized Medicine: Tailoring Treatments to Individual Genetic Profiles. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES *3*(3):42-45.